Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?

Eur J Neurosci. 2019 Feb;49(3):399-409. doi: 10.1111/ejn.14173. Epub 2018 Nov 15.

Abstract

The drive to develop drugs to treat PD starts and ends with the patient. Herein, we discuss how the experience with drug development for LID has led the field in translational studies in PD with advancing ground-breaking science via rigorous clinical trial design, to deliver clinical proof-of-concepts across multiple therapeutic targets. However, issues remain in advancing drugs efficacious preclinically to the clinic, and future studies need to learn from past successes and failures. Such lessons include implementing better early indicators of tolerability, for instance evaluating non-motor symptoms in preclinical models; improving patient-related outcome measures in clinical trials, as well as considering the unique nature of dyskinesia in an individual patient. The field of translational studies needs to become more patient focused to improve successful outcomes.

MeSH terms

  • Animals
  • Drug Development / methods*
  • Dyskinesia, Drug-Induced / complications
  • Dyskinesia, Drug-Induced / drug therapy*
  • Humans
  • Levodopa / adverse effects*
  • Parkinson Disease / complications
  • Parkinson Disease / drug therapy
  • Translational Research, Biomedical / standards

Substances

  • Levodopa